Artal Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Artal Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-150,000	Closed	-$11.3M	–	149
2021 Q1	$11.3M	Hold	150,000	–	–	0.2%	93
2020 Q4	$13.2M	Hold	150,000	–	–	0.28%	82
2020 Q3	$11.4M	Buy	+150,000	New	+$15.2M	0.28%	72
2020 Q2	–	Sell	-200,000	Closed	-$16.9M	–	136
2020 Q1	$16.9M	Buy	200,000 +100,000	+100%	+$8.62M	0.71%	34
2019 Q4	$8.46M	Buy	+100,000	New	+$7.55M	0.33%	53
2019 Q1	–	Sell	-200,000	Closed	-$17M	–	108
2018 Q4	$17M	Hold	200,000	–	–	0.63%	33
2018 Q3	$19.4M	Hold	200,000	–	–	0.5%	29
2018 Q2	$18.8M	Hold	200,000	–	–	0.4%	26
2018 Q1	$16.2M	Buy	200,000 +100,000	+100%	+$8.58M	0.2%	38
2017 Q4	$8.92M	Hold	100,000	–	–	0.13%	47
2017 Q3	$9.31M	Sell	100,000 -50,000	-33%	-$4.42M	0.16%	47
2017 Q2	$13.6M	Buy	150,000 +100,000	+200%	+$9.1M	0.24%	30
2017 Q1	$4.39M	Sell	50,000 -100,000	-67%	-$8.9M	0.1%	65
2016 Q4	$12.4M	Buy	+150,000	New	+$12.9M	0.28%	30
2016 Q1	–	Sell	-100,000	Closed	-$10.5M	–	63
2015 Q4	$10.5M	Hold	100,000	–	–	0.2%	49
2015 Q3	$10.5M	Sell	100,000 -100,000	-50%	-$13.4M	0.24%	47
2015 Q2	$27.4M	Hold	200,000	–	–	1.18%	25
2015 Q1	$24.9M	Sell	200,000 -100,000	-33%	-$10.6M	1.15%	23
2014 Q4	$27.1M	Buy	300,000 +100,000	+50%	+$8.32M	0.95%	22
2014 Q3	$14.4M	Sell	200,000 -200,000	-50%	-$13.1M	0.53%	34
2014 Q2	$24.9M	Buy	400,000 +200,000	+100%	+$12.1M	1.01%	20
2014 Q1	$13.6M	Sell	200,000 -300,000	-60%	-$22.1M	0.49%	45
2013 Q4	$35.2M	Buy	500,000 +300,000	+150%	+$20.4M	1.26%	11
2013 Q3	$14.4M	Hold	200,000	–	–	0.47%	31
2013 Q2	$11.1M	Buy	+200,000	New	+$12.5M	0.35%	40

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Artal Group's BMRN Position: Q3 2023 in Review

Artal Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 5,028 shares — an estimated $436K sold.

Artal Group first reported a position in BMRN in Q2 2013 and held it in 20 quarters. The position peaked at $59.8M in Q1 2015. 520 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Artal Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Artal Group sold 5,028 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $436K.
Artal Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 20 quarters.
Artal Group's BioMarin Pharmaceuticals position peaked at $59.8M in Q1 2015.
520 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.